{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:47:54Z","timestamp":1788871674023,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":5023,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1017\/s1041610210001985","type":"journal-article","created":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T10:48:58Z","timestamp":1288781338000},"page":"372-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Switching cholinesterase inhibitors in older adults with dementia"],"prefix":"10.1016","volume":"23","author":[{"given":"Fadi","family":"Massoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Eve","family":"Desmarais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1017\/S1041610210001985_bb0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1185\/030079902125000471","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil","volume":"18","author":"Auriacombe","year":"2002","journal-title":"Current Medical Research and Opinion"},{"key":"10.1017\/S1041610210001985_bb0015","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1185\/030079905X65655","article-title":"Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease","volume":"21","author":"Bartorelli","year":"2005","journal-title":"Current Medical Research and Opinion"},{"key":"10.1017\/S1041610210001985_bb0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/gps.542","article-title":"Switching cholinesterase inhibitor therapy in Alzheimer's disease: donepezil to rivastigmine, is it worth it","volume":"17","author":"Bullock","year":"2002","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610210001985_bb0025","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1177\/0269881106068299","article-title":"Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology","volume":"20","author":"Burns","year":"2006","journal-title":"Journal of Psychopharmacology"},{"key":"10.1017\/S1041610210001985_bb0030","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1368-5031.2005.00769.x","article-title":"Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment","volume":"60","author":"Dantoine","year":"2006","journal-title":"International Journal of Clinical Practice"},{"key":"10.1017\/S1041610210001985_bb0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1212\/WNL.59.4.563","article-title":"Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months","volume":"59","author":"Darreh-Shori","year":"2002","journal-title":"Neurology"},{"key":"10.1017\/S1041610210001985_bb0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrn1035","article-title":"Neurobiology of butyrylcholinesterase","volume":"4","author":"Darvesh","year":"2003","journal-title":"Nature Reviews Neurosciences"},{"key":"10.1017\/S1041610210001985_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3940(01)01586-5","article-title":"Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease","volume":"300","author":"Davidsson","year":"2001","journal-title":"Neuroscence Letters"},{"key":"10.1017\/S1041610210001985_bb0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjopharm.2006.06.002","article-title":"Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis","volume":"4","author":"Dybicz","year":"2006","journal-title":"American Journal of Geriatric Pharamacotherapy"},{"key":"10.1017\/S1041610210001985_bb0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/11318010-000000000-00000","article-title":"Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study","volume":"24","author":"Gardette","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1017\/S1041610210001985_bb0060","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1185\/030079906X132749","article-title":"A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study","volume":"22","author":"Gauthier","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"10.1017\/S1041610210001985_bb0065","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1532-5415.2007.01377.x","article-title":"A population-based study of cholinesterase inhibitor use for dementia","volume":"55","author":"Herrmann","year":"2007","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610210001985_bb0070","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00002512-200926050-00004","article-title":"Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study","volume":"26","author":"Herrmann","year":"2009","journal-title":"Drugs and Aging"},{"key":"10.1017\/S1041610210001985_bb0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jalz.2007.07.006","article-title":"Management of mild to moderate Alzheimer's disease and dementia","volume":"3","author":"Hogan","year":"2007","journal-title":"Alzheimers and Dementia"},{"key":"10.1017\/S1041610210001985_bb0080","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors","volume":"41","author":"Jann","year":"2002","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1017\/S1041610210001985_bb0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/157015910790909520","article-title":"Update on the pharmacological treatment of Alzheimer's disease","volume":"8","author":"Massoud","year":"2010","journal-title":"Current Neuropharmacology"},{"key":"10.1017\/S1041610210001985_bb0090","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology"},{"key":"10.1017\/S1041610210001985_bb0095","doi-asserted-by":"crossref","first-page":"451","DOI":"10.18553\/jmcp.2008.14.5.451","article-title":"Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease","volume":"14","author":"Mucha","year":"2008","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1017\/S1041610210001985_bb0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/ciia.2007.2.1.17","article-title":"Rivastigmine in the treatment of Alzheimer's disease: an update","volume":"2","author":"Onor","year":"2007","journal-title":"Clinical Interventions in Aging"},{"key":"10.1017\/S1041610210001985_bb0105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2990.1978.tb00545.x","article-title":"Changes in brain cholinesterases in senile dementia of Alzheimer type","volume":"4","author":"Perry","year":"1978","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1017\/S1041610210001985_bb0110","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/00002512-200623100-00006","article-title":"Galantamine extended release in Alzheimer's disease: profile report","volume":"23","author":"Robinson","year":"2006","journal-title":"Drugs and Aging"},{"key":"10.1017\/S1041610210001985_bb0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(00)00067-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a U.S. multicentre open-label study","volume":"10","author":"Rogers","year":"2000","journal-title":"European Neuropsychopharmacology"},{"key":"10.1017\/S1041610210001985_bb0120","first-page":"43","article-title":"Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study","volume":"7","author":"Sadowsky","year":"2005","journal-title":"Primary Care Companion to Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610210001985_bb0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1533317509333037","article-title":"Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease","volume":"24","author":"Sadowsky","year":"2009","journal-title":"American Journal of Alzheimer's Disease and Other Dementias"},{"key":"10.1017\/S1041610210001985_bb0130","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1517\/14656566.8.7.1011","article-title":"Donepezil: an update","volume":"8","author":"Seltzer","year":"2007","journal-title":"Expert Opinion Pharmacotherapy"},{"key":"10.1017\/S1041610210001985_bb0135","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"10.1017\/S1041610210001985_bb0140","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/gps.1301","article-title":"Switching from donepezil to galantamine: a double-blind study of two wash-out periods","volume":"20","author":"Wilkinson","year":"2005","journal-title":"International Journal of Geriatric Psychiatry"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224028977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224028977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610210001985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T12:50:06Z","timestamp":1736427006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224028977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1041610224028977"],"URL":"https:\/\/doi.org\/10.1017\/s1041610210001985","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching cholinesterase inhibitors in older adults with dementia","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610210001985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 International Psychogeriatric Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}